Peijun Ju1, Donghong Cui2. 1. Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 201108, China. 2. Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 201108, China manyucc@126.com.
Abstract
Schizophrenia is a severe mental illness that afflicts nearly 1% of the world population. Although the exact pathophysiology of schizophrenia is unknown, the N-methyl-d-aspartate receptor (NMDAR), a major glutamate receptor subtype, has received great attention. The NR1 subunit is often considered indispensable for functional NMDAR assemblies, abnormal modulation of which is found in patients with schizophrenia. In this review, we discuss how disrupted function of NR1 subunits in NMDAR leads to the progression and development of symptoms of schizophrenia-like behaviors in a variety of genetically modified mouse models. We also discuss some of the susceptible genes and shared signaling pathways among the schizophrenia, and how their mutations lead to NR1 subunits hypofunction. Finally, we suggest that the subunit-selective modulators of NR1 subunits in NMDA receptors may be promising tools for the therapy of schizophrenia.
Schizophrenia is a severe mental illness that afflicts nearly 1% of the world population. Although the exact pathophysiology of schizophrenia is unknown, the N-methyl-d-aspartate receptor (NMDAR), a major glutamate receptor subtype, has received great attention. The NR1 subunit is often considered indispensable for functional NMDAR assemblies, abnormal modulation of which is found in patients with schizophrenia. In this review, we discuss how disrupted function of NR1 subunits in NMDAR leads to the progression and development of symptoms of schizophrenia-like behaviors in a variety of genetically modified mouse models. We also discuss some of the susceptible genes and shared signaling pathways among the schizophrenia, and how their mutations lead to NR1 subunits hypofunction. Finally, we suggest that the subunit-selective modulators of NR1 subunits in NMDA receptors may be promising tools for the therapy of schizophrenia.
Authors: V Cheli; M Adrover; C Blanco; C Ferrari; A Cornea; F Pitossi; A L Epstein; D Jerusalinsky Journal: J Neurochem Date: 2006-04 Impact factor: 5.372
Authors: Thomas J McHugh; Matthew W Jones; Jennifer J Quinn; Nina Balthasar; Roberto Coppari; Joel K Elmquist; Bradford B Lowell; Michael S Fanselow; Matthew A Wilson; Susumu Tonegawa Journal: Science Date: 2007-06-07 Impact factor: 47.728
Authors: Caroline Brandão-Teles; Valéria de Almeida; Juliana S Cassoli; Daniel Martins-de-Souza Journal: Front Pharmacol Date: 2019-03-05 Impact factor: 5.810
Authors: Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj Journal: Front Pharmacol Date: 2019-12-09 Impact factor: 5.810
Authors: Kevin C F Fone; David J G Watson; Rodolphe I Billiras; Dorothee I Sicard; Anne Dekeyne; Jean-Michel Rivet; Alain Gobert; Mark J Millan Journal: Mol Neurobiol Date: 2020-01-20 Impact factor: 5.590